The use of hydroxyurea in severe forms of sickle cell disease: Study of 47 tunisian paediatric cases;L'utilisation de l'hydroxyurée dans les formes sévères de la drépanocytose : étude de 47 cas pédiatriques tunisiens

Archives de Pediatrie

Volumn 15, Issue 1, 2008, Pages 24-28

  Mellouli, F ^a   Bejaoui, M ^a  

^a Centre national de greffe de moelle osseuse de Tunis   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN F; HYDROXYUREA;

ACUTE CHEST SYNDROME; ADOLESCENT; ADULT; APHTHOUS STOMATITIS; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; ERYTHROBLASTOPENIA; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LYMPHOCYTE COUNT; MACULOPAPULAR RASH; NEUTROPENIA; NEUTROPHIL; RECURRENCE RISK; RISK REDUCTION; SICKLE CELL ANEMIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUNISIA;

ANEMIA, SICKLE CELL; CHILD; HETEROZYGOTE; HOMOZYGOTE; HOSPITALIZATION; HUMANS; HYDROXYUREA; LENGTH OF STAY; PROSPECTIVE STUDIES; THALASSEMIA; TUNISIA;

EID: 38349140094     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2007.09.013     Document Type: Article

References (23)

1. Aliyu Z.Y., Tumblin A.R., and Kato G.J. Current therapy of sickle cell disease. Haematologica 90 (2005) 7-10
2. Armolia P.J., Almeida A., Halsey C., et al. Therapeutic challenges in childhood sickle cell disease part 1: current and future treatment options. Br J Haematol 120 (2003) 725-736
3. Ferster A., Vermylen C., Cornu G., et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 88 (1996) 1960-1964
4. Armolia P.J., Almeida A., Davies S.C., et al. Therapeutic challenges in childhood sickle cell disease part 2: a problem oriented approach. Br J Haematol 120 (2003) 737-743
5. Olivieri N.F., and Vichinsky E.P. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol 20 (1998) 26-31
6. Hankins J.S., Ware R.E., Rogers Z.R., et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extention study. Blood 106 (2005) 2269-2275
7. Weiner D.L., and Brugnara C. Hydroxyurea and sickle cell disease: a chance for every patient. JAMA 289 (2003) 1692-1694
8. Steinberg M.H., Barton F., Castro O., et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289 (2003) 1645-1651
9. Helton K.J., Wang W.C., Wynn L.W., et al. The effect of hydroxyurea on vasculopathy in a child with sickle cell disease. Am J Neuroradiol 23 (2002) 1692-1696
10. Sumoza A., De Bisotti R., Sumoza D., et al. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol 71 (2002) 161-165
11. Ware R.E., Zimmerman S.A., and Schultz W.H. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sicle cell disease. Blood 94 (1999) 3022-3026
12. De Montalembert M., Brousse V., Elie C., et al. Long-term hydroxyurea treatment in children with sickle cell disease: Tolerance and clinical outcomes. Haematologica 91 (2006) 125-128
13. Gulbis B., Haberman D., Dutour D., et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: The Belgian experience. Blood 105 (2005) 2685-2690
14. Kinney T.R., Helms R.W., O'Branski E.E., et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS Study, a Phase I/II Trial. Blood 94 (1999) 1550-1554
15. Ferster A., Tahiri P., Vermylen C., et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 97 (2001) 3628-3632
16. De Montalembert M., and Davies S.C. Is hydroxyurea leukemogenic in children with sickle cell disease?. Blood 98 (2001) 2878-2879
17. De Montalembert M., Begue P., Bernaudin F., et al. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. Arch Dis Child 81 (1999) 437-439
18. Rigano P., Rodgers G.P., Renda D., et al. Hemoglobin 25 (2001) 9-17
19. Zimmerman S.A., Schultz W.H., Dvis J.S., et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103 (2004) 2039-2045
20. Davies S.C., and Gilmore A. The role of hydroxyurea in the management of sickle cell disease. Blood Rev 17 (2003) 99-109
21. Charache S., Terrin M.L., Moore R.D., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332 (1995) 1317-1322
22. Powers D.R. Hydroxyurea in very young children with sickle cell anemia is not a cure-all. J Pediatr 139 (2001) 763-764
23. Wang W.C., Wynn L.W., Rogers Z.R., et al. A two-years pilot trial of hydroxyurea in very young children with sickle cell anemia. J Pediatr 139 (2001) 790-796